These results demonstrate an enhanced anti-tumor immunity that could help overcome trastuzumab resistance, especially if T-Dxd was combined with an anti-PD-1 antibody, to account for the elevated PD-L1 expression induced by TDxd. This evidence concerns the gene CD274 and neoplasm.